Statement of Deficiencies	**(X1) Provider/Supplier/CLIA Identification Number**	**(X3) Date Survey Completed**
	44D2059877	01/07/2025
Name of Provider or Supplier	**Street Address, City, State**	
Family Care Walk-In Clinic, Inc	400 Us Hwy 45w, Humboldt, TN	

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on a review of the Centers for Medicare and Medicaid Services (CMS) Casper report 0155D (CMS 155), the laboratory's American Proficiency Institute (API) proficiency testing (PT) records, and staff interview, the laboratory failed to maintain successful participation for two consecutive PT events in 2024 for the White Blood Cell (WBC) Differential (WBC DIFF) analyte, resulting in initial unsuccessful PT performance. (Refer to D2130)
D2130	HEMATOLOGY CFR(s): 493.851(f)

	(f) Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of the CMS 155, the laboratory's API PT records, and staff interview, the laboratory failed to maintain successful participation for two consecutive PT events in 2024 for the WBC DIFF analyte, resulting in initial unsuccessful PT performance. The findings include: 1. A review of the CMS 155 report revealed the following scores for the WBC DIFF analyte: 2024 Event Two- 0% 2024 Event Three- 33% 2. A review of the API PT performance evaluation reports revealed the following overall scores for the WBC DIFF analyte: 2024 Event Two- 0% 2024 Event Three- 33% 3. An electronic interview with the laboratory technical consultant on 01/07/2025 at 12:12 p.m. confirmed the survey findings. Word Key %- Percent